SecBot SecBot
SECBOTREPLAY Home › Report › ONC

ONC · BeOne Medicines filed its STAR Market interim report (H1 2026) in…

BeOne Medicines Ltd. · 8-K filed Aug 26, 2026 at 06:14 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Aug 26, 2026 at 06:14 ET

BeOne Medicines filed its STAR Market interim report (H1 2026) in China, disclosing R&D spending breakdown by key product in accordance with PRC GAAP. The filing is a routine dual-listing disclosure requirement, not a standalone earnings release. It provides incremental transparency on pipeline investment allocation but contains no new financial results or guidance beyond what was released in the Q2 2026 earnings report on August 5, 2026.

  • Filed PRC GAAP-based interim report with Shanghai Stock Exchange STAR Market for H1 2026
  • Disclosed R&D expenses allocated by key products: BEQALZI ($74M), tacabrutideg ($44M), BRUKINSA ($43M), TEVIMBRA ($37M), BGB-43395 ($23M)
  • Total U.S. GAAP R&D spend for H1 2026: $1.15B (vs $1.01B in H1 2025)
  • Material accounting differences between PRC GAAP and U.S. GAAP on share-based compensation, income taxes, and leasing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access